Statins Don't Lower LDL. Your Liver Does.

⚡ Clinical Takeaway

Domain	Key Finding	Evidence Level
Primary mechanism	Statins inhibit HMG-CoA reductase → hepatic sterol deficit activates SREBP-2 → LDL receptor upregulation → accelerated ApoB particle clearance from plasma	Established molecular biology
Pleiotropic effects	Anti-inflammatory, endothelial, and plaque-stabilizing effects are real and measurable — but the RCT evidence favors LDL lowering, not pleiotropy, as the dominant CV risk driver	Replicated RCTs + Mendelian randomization
Natural experiment	PCSK9 inhibitors and ezetimibe lower LDL via non-statin mechanisms with proportional CV benefit — arguing against pleiotropic indispensability	IMPROVE-IT, FOURIER, ODYSSEY
Clinical takeaway	The mechanism of LDL lowering matters less than achieving target ApoB/LDL-C. Combination therapy (statin + ezetimibe ± PCSK9 inhibitor) is mechanistically justified and outcomes-validated	ACC/AHA Guideline-concordant

Statins Don't Lower LDL.Your Liver Does.